MEMORANDUM

December 20, 1989

SUBJECT: Interpretation of the Good Laboratory Practice (GLP) Regulation

GLP Regulations Advisory No. 6

FROM: David L. Dull, Director
Laboratory Data Integrity Assurance Division

TO: GLP Inspectors

Please find attached an interpretation of the GLP regulations as issued by the Policy & Grants Division of the Office of Compliance Monitoring. This interpretation is official policy in the GLP program and should be followed by all GLP inspectors.

For further information, please contact Francisca E. Liem at FTS-475-9864.

Attachment

cc: C. Musgrove
Dear

This is in response to your letter of February 22, 1990, to Steve Howie regarding compliance with Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) Good Laboratory Practice standards (GLPs). In your letter you requested clarification regarding what may constitute a study under GLPs.

You proposed that in residue and environmental fate studies that the field portions and analytical laboratory portions of such studies be allowed to be considered as separate studies (i.e., analytical studies and field application studies). For the purpose of GLPs you pointed out that there would be practical benefits in localizing study control in terms of standard operating procedures and the responsibilities of the testing facility management, the study director, and the quality assurance unit (QAU) a study monitor at the sponsor facility would oversee the work performed by the study directors. Finally, reports submitted to EPA would be formatted to comply with PR 86-5.

It is our belief that this approach does not meet GLP requirements. The term "study," as defined at 40 CFR 160 3, is an experiment “in which a test substance is studied in a test system ... to determine or help predict its effects...” The coverage of portions of studies (analytical phase or field application phase) complete and separate studies under this definition is problematic.

The term study director is defined as the individual responsible for the overall conduct of the study. At 40 CFR 160. 33, it is further explained that the study director is the single point in study control and is responsible for the interpretation, analysis, documentation and reporting of results. This clearly indicates that a need is perceived for an individual who has overall responsibilities that would encompass all technical aspects of a study. When a study is submitted to EPA, it is assumed that there was one study director responsible for the overall conduct of the study.

Some technical difficulties arise from the breaking of studies into components parts identified separately as studies. For example, there could be difficulty in assessing who has responsibility during certain critical phases of studies, such as
the transfer of sample material from application sites following analysis, and the archiving of data. The study directors of each unit of such a subdivided study would also have the authority to account for protocol changes as provided in 40 CFR 160.120(b). This would be expedient, but there would be a loss of assurance that such changes conform to the overall purpose of the study.

Subdividing a study could also increase the overall burden associated with performing the study. It would be necessary to address the entire GLP standard from the viewpoint of each subunit that is described as a study. For example, cooperators involved in application of agricultural chemicals would have to address test substance characterization as required at 40 CFR 160.105 if the application work is a separate study. Each time that a subunit exceeds 4 weeks duration, the affected contracting testing facility would also be responsible for assuring that a reserve sample of the test substance is retained. Reporting requirements at 40 CFR 160.185 would have to be set for each unit. And since EPA interprets 40 CFR 160.35(b)(3) to require a QAU inspection of each study, each subdivision would require at least one QAU inspection.

It should be possible to accommodate entire field residue or environmental fate experiments as single studies under GLPs. The testing facility that is involved in such studies would encompass all organizational entities involved in conducting the actual work. Testing facility management duties may be predominately assumed by the sponsor facility or by a lead contracting laboratory, depending on needs and capabilities. Certain overall responsibilities, such as that of the study director to assure that the study is conducted according to GLPs, must be centralized and cannot be delegated. However, the study could be divided into units based on practical considerations, with many technical details and the responsibility of monitoring these details delegated as is seen fit by management. Thus, study project directors, or other appropriately identified individuals, may be responsible for assuring that day-to-day operations are carried out.

Please note that the testing facility management is responsible for designating the study director and making the appropriate assurances as specified at 40 CFR 160.31 (e.g., that there is a QAU, etc.). The regulations do not state that the testing facility management actually performs the duties it is providing assurances for under this section; consequently, there is considerable flexibility for contracted persons to provide their own standard operating procedures, QAUs, or other requirements, provided that the overall testing facility management (i.e., at the sponsor, or perhaps at the prime contractor) can provide assurance that compliance with GLPs occurred.

If you have any questions concerning this response, please
contact Steve Howie of my staff at (202) 475-7786

Sincerely yours,

/s/John J. Neylan III, Director
Policy and Grants Division
Office of Compliance Monitoring

cc: David L. Dull
    GLP File